<bill session="112" type="s" number="1972" updated="2020-02-10T17:06:53Z">
  <state datetime="2011-12-08">REFERRED</state>
  <status>
    <introduced datetime="2011-12-08"/>
  </status>
  <introduced datetime="2011-12-08"/>
  <titles>
    <title type="short" as="introduced">Food and Drug Administration Mission Reform Act of 2011</title>
    <title type="display">Food and Drug Administration Mission Reform Act of 2011</title>
    <title type="official" as="introduced">A bill to amend the Food and Drug Administration's mission.</title>
  </titles>
  <sponsor bioguide_id="C000542"/>
  <cosponsors>
    <cosponsor bioguide_id="A000368" joined="2011-12-08"/>
  </cosponsors>
  <actions>
    <action datetime="2011-12-08">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2011-12-08" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="112" type="h" number="3214" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Licensing and registrations"/>
  </subjects>
  <amendments/>
  <summary date="2014-12-06T14:32:21Z" status="Introduced in Senate">Food and Drug Administration Mission Reform Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise the mission of the Food and Drug Administration (FDA) to include establishment of a regulatory system that: (1) advances medical innovation by incorporating modern scientific tools, standards, and approaches; (2) protects the public health and enables patients to access novel products while promoting economic growth, innovation, competitiveness, and job creation among the industries regulated by the FFDCA; (3) is based on the best available science; (4) allows for public participation and an open exchange of ideas; (5) promotes predictability, allows flexibility, and reduces uncertainty; (6) identifies and uses the most innovative and least burdensome tools for achieving regulatory ends; (7) ensures that regulations are accessible, consistent, transparent, written in plain language, and easy to understand; (8) measures, and seeks to improve, the actual results of regulatory requirements; and (9) incorporates a patient-focused benefit-risk framework that accounts for varying degrees of risk tolerance.</summary>
</bill>
